State of the art: IBD therapy and clinical trials in IBD.
about
Microparticles as controlled drug delivery carrier for the treatment of ulcerative colitis: A brief reviewEvidence-based clinical practice guidelines for Crohn's disease, integrated with formal consensus of experts in JapanRecent advances in orally administered cell-specific nanotherapeutics for inflammatory bowel diseaseRole of interleukin 6 in a murine model of Crohn's ileitis: are cytokine/anticytokine strategies the future for IBD therapies?Diagnosis of ulcerative colitis before onset of inflammation by multivariate modeling of genome-wide gene expression data.White spots on the mucosal surface of the duodenum in dogs with lymphocytic plasmacytic enteritis.Role of selective cyclooxygenase-2 inhibitors in exacerbation of inflammatory bowel disease: A systematic review and meta-analysisCranberry proanthocyanidins improve the gut mucous layer morphology and function in mice receiving elemental enteral nutrition.Genetic Polymorphisms of IL-17F and TRAF3IP2 Could Be Predictive Factors of the Long-Term Effect of Infliximab against Crohn's DiseaseAdsorptive granulocyte/monocyte apheresis for the maintenance of remission in patients with ulcerative colitis: a prospective randomized, double blind, sham-controlled clinical trial.Use of antibiotics in the treatment of inflammatory bowel disease.Aberrant activation of nuclear factor of activated T cell 2 in lamina propria mononuclear cells in ulcerative colitis.A new animal model of postsurgical bowel inflammation and fibrosis: the effect of commensal microflora.Investigation of mitigating effect of colon-specific prodrugs of boswellic acid on 2,4,6-trinitrobenzene sulfonic acid-induced colitis in Wistar rats: Design, kinetics and biological evaluation.Current status and future perspectives of leukocytapheresis for inflammatory bowel disease.The role of anti(myco)bacterial interventions in the management of IBD: is there evidence at all?Life, death, and miracles: Th17 cells in the intestine.Oxidative Stress and DNA Damage: Implications in Inflammatory Bowel Disease.Inflammatory Bowel Disease: Updates on Molecular Targets for Biologics.Novel guggulsterone derivative GG-52 inhibits NF-kappaB signaling in intestinal epithelial cells and attenuates acute murine colitis.Cranberry proanthocyanidins improve intestinal sIgA during elemental enteral nutrition.Retinoic acid-induced gut tropism improves the protective capacity of Treg in acute but not in chronic gut inflammation.Relevance of the processed blood volume per granulocyte and monocyte apheresis session to its clinical efficacy in patients with ulcerative colitis.Oral IL-10 gene delivery in a microsphere-based formulation for local transfection and therapeutic efficacy in inflammatory bowel disease.Ex vivo simulation of IgG Fc and T-cell receptor functions: an application to inflammatory bowel disease.Drug nanocarriers to treat autoimmunity and chronic inflammatory diseases.
P2860
Q26743907-3EFDF417-1128-4262-9449-83BB7BB79E62Q26829392-6C7FAE42-EC71-45B8-9367-F26087A893C0Q28073219-50BA4F44-9158-48F2-8C2B-09090B31A599Q30438775-A82F49F2-1801-45F2-A6E1-25483E24A106Q33403787-609ECA0B-9A7C-4B82-8CEB-746462EBB312Q35013948-C183ACAA-A316-4FEB-B6EA-F4B8B697FFF2Q35137854-50A20115-5B8F-4284-8918-DF51FB695EF4Q36044764-39D17242-A247-4B8C-B8EB-A0A7A3FE4C54Q36237186-C81A4813-16AB-4659-9AFB-E7476477A761Q36385158-654226E2-C321-4CEE-A321-73E4A736209FQ36521201-65F83A49-18FC-4C7B-9F3A-3AF729ECF5EBQ37226310-B96D9375-CBAE-4B02-85F0-E22774061FCDQ37363427-30428B71-0CE8-48AC-AF4D-0179A193BAA4Q37662616-3D12CE3F-4ED4-4164-A1E9-F331C196CA35Q37993226-499AAEA9-FF50-493A-8603-822E94D758E2Q38026395-335AE3F4-BFE9-455B-957D-0B547DB2D91EQ38040744-7B20863E-D619-4F8D-9645-CDFDA7E5A1CEQ38550831-00B472C5-B3D9-470E-AEEF-49349C705634Q39293951-74836A93-4EA2-4FA3-9058-83859EABF0D1Q39733524-F325C397-018D-4DED-BC2D-C9F8EF1E0C9EQ40125219-79DA1A4B-FC35-41F2-BEF3-E657113B8CEEQ42944527-9C91A218-B4A8-4E74-A551-D07E12643833Q44433975-77C795A3-4368-4EBD-871A-76D1A3CC4996Q45876830-DC4672EB-B63A-4BA6-9B8D-E2784B01A3D2Q45958686-DF00415E-8B34-47FA-BB32-55A87E7063C3Q50268454-2693D8B1-FC43-4F29-BD76-F1206A756928
P2860
State of the art: IBD therapy and clinical trials in IBD.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
State of the art: IBD therapy and clinical trials in IBD.
@ast
State of the art: IBD therapy and clinical trials in IBD.
@en
type
label
State of the art: IBD therapy and clinical trials in IBD.
@ast
State of the art: IBD therapy and clinical trials in IBD.
@en
prefLabel
State of the art: IBD therapy and clinical trials in IBD.
@ast
State of the art: IBD therapy and clinical trials in IBD.
@en
P2093
P2860
P1476
State of the art: IBD therapy and clinical trials in IBD.
@en
P2093
Bruce E Sands
James D Lewis
Kim L Isaacs
Stephan R Targan
P2860
P356
10.1097/01.MIB.0000184852.84558.B2
P478
11 Suppl 1
P577
2005-11-01T00:00:00Z